| Bioactivity | TCS 2510 is a selective EP4 agonist. TCS 2510 can be used for the research of metabolic diseases[1]. |
| Target | EP4 |
| Invitro | TCS 2510 (0.001~100 μM; GLUTag cells) stimulates glucagon like peptide 1 secretion. TCS2510 activates the Gas signaling pathway. TCS 2510 (10 μM; 2~24 h; GLUTag cells) increases the Gcg mRNA expression levels. TCS 2510 produces a concentration dependent increase in cAMP levels in GLUTag cells with EC50 of 20 nM and the maximal stimulation of 60 % over the basal cAMP levels. The decrease in cell impedance in GLUTag cells observed with TCS 2510 is concentration dependent with IC50 of 15 nM. TCS 2510 produces a concentration-dependent increase in glucagon like peptide 2 secretion in GLUTag cells[1]. |
| In Vivo | TCS 2510 (0.1~10 mg/kg; p.o.) produces a dose-dependent elevation in plasma glucagon like peptide 1 levels in fasted mice measured 15 min after compound administration[1].TCS 2510 (10 mg/kg; p.o.) increases plasma glucagon like peptide 1 levels up to 8-fold over the basal hormone levels[1].TCS 2510 (1~10 mg/kg; p.o) affords a significant elevation in plasma glucagon like peptide 2 levels[1] Animal Model: |
| Name | TCS 2510 |
| CAS | 346673-06-1 |
| Formula | C21H29N5O2 |
| Molar Mass | 383.49 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Solution, -20°C, 2 years |
| Reference | [1]. Coskun T, et al. Activation of prostaglandin E receptor 4 triggers secretion of gut hormone peptides GLP-1, GLP-2, and PYY. Endocrinology. 2013;154(1):45-53. |